GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halozyme Therapeutics Inc (FRA:RV7) » Definitions » Cash Flow for Dividends

Halozyme Therapeutics (FRA:RV7) Cash Flow for Dividends : €0.0 Mil (TTM As of Sep. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Halozyme Therapeutics Cash Flow for Dividends?

Halozyme Therapeutics's cash flow for dividends for the three months ended in Sep. 2024 was €0.0 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Sep. 2024 was €0.0 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Halozyme Therapeutics Cash Flow for Dividends Historical Data

The historical data trend for Halozyme Therapeutics's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halozyme Therapeutics Cash Flow for Dividends Chart

Halozyme Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Halozyme Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Halozyme Therapeutics Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halozyme Therapeutics Cash Flow for Dividends Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's Cash Flow for Dividends provided by GuruFocus.com. Please click on the following links to see related term pages.

Halozyme Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halozyme Therapeutics Inc (FRA:RV7) » Definitions » Cash Flow for Dividends
Comparable Companies
CORT BPMC VKTX CYTK NUVL KRYS TGTX IONS CRNX RNA VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
HALO:USA 0J2O:UK
Address
12390 El Camino Real, San Diego, CA, USA, 92130
Website
https://www.halozyme.com
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Halozyme Therapeutics Headlines

No Headlines